CStone Pharma, a young Shanghai-Suzhou startup, reported that its application for clinical trials of a recombinant PD-L1 antibody was accepted for review by the CFDA. According to CStone, the candidate (WBP3155) is China’s first innovative, fully humanized, full-length original format Immunoglobulin G (IgG) mAb candidate. WBP3155 was produced by the OMT platform, which suggests a connection with WuXi AppTec. WuXi in-licensed rights to the OMT platform for mAb discovery. In July, CStone raised $150 million in an A round from three China investors including WuXi Healthcare Ventures.
